Establishment Labs Holdings Inc

Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Establishment Labs posts strong revenue growth and sets ambitious targets

Establishment Labs reported strong revenue growth in Q4 2022 and outlined ambitious revenue guidance for 2023, supported by strategic product launches and market expansion initiatives.
While facing challenges in managing expenses and optimizing margins, the company's focus on growth opportunities and market transformation positions it for long-term success and achieving its revenue targets.
With a solid cash position, investments in new facilities, and a clear roadmap for future growth, Establishment Labs demonstrates resilience and strategic foresight in navigating the competitive landscape.

Establishment Labs (ESTA) reports robust Q1 revenue growth and global expansion

Establishment Labs Holdings Inc (ESTA) delivered strong revenue growth and strategic advancements in Q1 2023, positioning the company for future success.
While facing challenges in managing expenses and entering new markets, the company's focus on innovation and global expansion presents promising opportunities.
With a solid financial foundation and a clear growth strategy, ESTA is poised to capitalize on market demand and drive sustainable growth in the coming quarters.

Establishment Labs Holdings Inc reports strong Q2 growth and eyes expansion in China and Europe

Establishment Labs Holdings Inc's Q2 2023 performance showcased revenue growth and strategic advancements, despite challenges in profitability margins.
The company's focus on expanding into new markets, launching innovative products, and strengthening partnerships presents promising growth opportunities.
Maintaining revenue guidance, preparing for new launches, and addressing operational challenges position the company for a strong finish to 2023.

Establishment Labs maintains revenue amid global slowdown, eyes future growth

Establishment Labs faces challenges from a global slowdown in aesthetics procedures but sees opportunities in new markets and innovative products.
The company's focus on cost control and cash preservation aligns with expectations of positive EBITDA and cash flow in the future.
Key strengths include FDA clearances, positive study outcomes, and confidence in growth prospects beyond 2023.

Establishment Labs (ESTA) reports robust Q4 revenue and eyes global expansion

Establishment Labs Holdings Inc (ESTA) demonstrated strong revenue growth and cost management in Q4 2023.
The company faces challenges in gross profit and cash utilization but is poised for improved margins and profitability in 2024 and beyond.
Opportunities lie in global expansion, market penetration with innovative products, and a focus on achieving positive cash flow in the near future.

Establishment Labs reports strong Q1 revenue and eyes global growth

Establishment Labs Holdings Inc showed strong Q1 performance with revenue of $37.2 million.
The company aims to achieve positive adjusted EBITDA by end of 2024 and positive cash flow by end of 2025.
Progress in FDA approvals, market diversification, and strategic expansion plans are key strengths.
Challenges include addressing net losses, achieving positive EBITDA, and upcoming FDA inspection.

Establishment Labs Holdings Inc reports strong Q2 performance and eyes U.S. and China growth

Establishment Labs Holdings Inc demonstrated strong revenue growth and progress towards profitability in Q2 2024.
While facing challenges in Latin America, the company is capitalizing on opportunities in the U.S. and China markets.
With a focus on new product launches and improving gross margins, the company is poised for future growth and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, June  11, 2020  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has received CE Mark for the Motiva Flora Tissue Expander.

Establishment Labs’ Motiva Flora Tissue Expander Receives CE Mark

Establishment Labs Holdings Inc. (ESTA) CEO Juan José Chacón-Quirós on Q1 2020 Results - Earnings Call Transcript

As of late, it has definitely been a great time to be an investor Establishment Labs

Will Establishment Labs Continue to Surge Higher?

Co-Diagnostics

Novocure

OncoCyte

Medical Services Outlook Bright Amid Coronavirus Crisis

NEW YORK, March  25, 2020  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that the U.S. Patent & Trademark Office has issued a patent protecting its proprietary implant surface technology. U.S. Patent No. 10,595,979, which extends protection to March 2035, covers breast implant surface technology associated with increased biocompatibility. The ‘979 patent epitomizes the Company’s dedication to improving patient safety and post-operative outcomes by advancing technology.

Establishment Labs Receives Issuance for Key U.S. Patent  Covering Company’s Implant Surface Technology

Establishment Labs Holdings, Inc. (ESTA) CEO Juan Jose Chacon Quiros on Q4 2019 Results - Earnings Call Transcript

NEW YORK, Feb.  03, 2020  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – today announced the closing of its previously announced public offering of 2,628,571 common shares at $26.25 per share. This includes the exercise in full by the underwriters of their option to purchase up to 342,857 additional common shares. The gross proceeds to Establishment Labs were approximately $69.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Establishment Labs.

Establishment Labs Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK, Dec.  05, 2019  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on Women’s Health – initially in the breast aesthetics and reconstruction market – announced its one millionth Motiva® implant in market.

ESTA Reaches One Million Motiva Implants Milestone

Establishment Labs Holdings, Inc. (ESTA) CEO Juan Jose Chacon Quiros on Q3 2019 Results - Earnings Call Transcript

Science, technology, safety and clinical outcomes of Motiva Implants® showcased as symposium breaks attendance records Science, technology, safety and clinical outcomes of Motiva Implants® showcased as symposium breaks attendance records

Establishment Labs Recaps Fifth Annual World Symposium on Ergonomic Implants

NEW YORK, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a key patent application covering its proprietary implant surface technology. Acquired from the University of Manchester, this critical research and patent application was funded with the cooperation of Establishment Labs and is an important component of Motiva Implants®. The University of Manchester’s Institute of Inflammation and Repair is one of the world’s leading innovators of biocompatible surfaces within the human body.

Establishment Labs Receives Notice of Allowance for Key U.S. Patent Application Covering Company’s Implant Surface Technology and Announces 510(k) Submission for its Tissue Expander

NEW YORK, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós will participate in a fireside chat presentation at the Morgan Stanley 17th Annual Global Healthcare Conference, on Wednesday, September 11, 2019 at 12:15 p.m. Eastern Time in New York City.

Establishment Labs to Participate in the Morgan Stanley 17th Annual  Global Healthcare Conference

Establishment Labs Holdings Inc. (ESTA) CEO Juan José Chacón-Quirós on Q2 2019 Results - Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) CEO Juan José Chacón-Quirós on Q1 2019 Results - Earnings Call Transcript

Establishment Labs (ESTA) has taken the breast implant industry by storm with its next level technology, 6th generation, Motiva Implants.

The FDA Might Have Inadvertently Implanted Establishment Labs As The Next Hot Medtech Stock

Establishment Labs Holdings Inc. (ESTA) CEO Juan José Chacón-Quirós on Q4 2018 Results - Earnings Call Transcript

News for Establishment Labs Holdings Inc Stock (ESTA)